Novel models for predicting individualized outcomes in patients with advanced hepatocellular carcinoma receiving immunotherapy - Takeaways - MDSpire

Novel models for predicting individualized outcomes in patients with advanced hepatocellular carcinoma receiving immunotherapy

  • By

  • Chao Chen

  • Yang Wang

  • Yan Zhao

  • Wenyan Cao

  • Ao Chen

  • Xiufeng Liu

  • Zhan Shi

  • Jie Shen

  • June 1, 2026

  • 0 min

Share

  • 1

    A nomogram was developed to differentiate hepatocellular carcinoma patients for immunotherapy and assess their risk levels.

  • 2

    The study analyzed 328 HCC patients treated with anti-PD-1 drugs from January 2019 to December 2022.

  • 3

    Prognostic factors for progression-free survival included treatment sequence and disease progression with bone or lymph node involvement.

  • 4

    The overall survival model achieved C-indices of 0.787 for training and 0.671 for validation cohorts, indicating reliable predictive performance.

  • 5

    The nomogram effectively predicted survival benefits in intermediate and advanced-stage HCC patients undergoing immunotherapy.

Original Source(s)

Novel models for predicting individualized outcomes in patients with advanced hepatocellular carcinoma receiving immunotherapy

  • by Chao Chen, Yang Wang, Yan Zhao, Wenyan Cao, Ao Chen, Xiufeng Liu, Zhan Shi, Jie Shen

  • June 1, 2026

Related Content

This Week’s CGT News: Base Editing Takes Aim at Cholesterol

Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M

  • June 1, 2026

  • 5 min
Retraction: Exosome component 4 promotes epithelial ovarian cancer cell proliferation, migration, and invasion via the Wnt pathway

  • June 1, 2026

Balloon-occluded hepatic arterial infusion for unresectable hepatocellular carcinoma: a phase II trial interim analysis